Mirum Pharmaceuticals, Inc. Employee Directory
Pharmaceutical ManufacturingCalifornia, United States201-500 Employees
Mirum Pharmaceuticals, Inc. is a mid-sized pharmaceutical company based in Foster City, California, that concentrates on rare diseases. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis. The organization combines deep rare-disease expertise with engagement with patient communities to support its development and access efforts. Its clinical-stage pipeline features volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis and primary biliary cholangitis; brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus; and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome. In 2026, the company announced positive Phase 2b data for volixibat in PSC at the EASL International Liver Congress. It also reported regulatory progress with the U.S. FDA related to zilurgisertib during the year.
1-888-653-2347 
support@leadiq.com 
